JP2023508469A5 - - Google Patents

Info

Publication number
JP2023508469A5
JP2023508469A5 JP2022539383A JP2022539383A JP2023508469A5 JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5
Authority
JP
Japan
Application number
JP2022539383A
Other languages
Japanese (ja)
Other versions
JPWO2021134086A5 (https=
JP7644122B2 (ja
JP2023508469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067235 external-priority patent/WO2021134086A1/en
Publication of JP2023508469A publication Critical patent/JP2023508469A/ja
Publication of JP2023508469A5 publication Critical patent/JP2023508469A5/ja
Publication of JPWO2021134086A5 publication Critical patent/JPWO2021134086A5/ja
Priority to JP2025029197A priority Critical patent/JP2025090628A/ja
Application granted granted Critical
Publication of JP7644122B2 publication Critical patent/JP7644122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539383A 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 Active JP7644122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029197A JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962953611P 2019-12-26 2019-12-26
US62/953,611 2019-12-26
US202063037044P 2020-06-10 2020-06-10
US63/037,044 2020-06-10
US202063093830P 2020-10-20 2020-10-20
US63/093,830 2020-10-20
PCT/US2020/067235 WO2021134086A1 (en) 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029197A Division JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Publications (4)

Publication Number Publication Date
JP2023508469A JP2023508469A (ja) 2023-03-02
JP2023508469A5 true JP2023508469A5 (https=) 2023-12-20
JPWO2021134086A5 JPWO2021134086A5 (https=) 2023-12-20
JP7644122B2 JP7644122B2 (ja) 2025-03-11

Family

ID=74195194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539383A Active JP7644122B2 (ja) 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Country Status (10)

Country Link
US (2) US11344510B2 (https=)
EP (1) EP4081301A1 (https=)
JP (2) JP7644122B2 (https=)
KR (1) KR20220131520A (https=)
CN (2) CN115190815B (https=)
AU (1) AU2020415511A1 (https=)
CA (1) CA3165903A1 (https=)
IL (1) IL294202A (https=)
MX (1) MX2022007994A (https=)
WO (1) WO2021134086A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
CN115190815B (zh) * 2019-12-26 2024-06-18 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
KR20230124103A (ko) 2020-02-18 2023-08-24 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
CA3220228A1 (en) 2021-05-25 2022-12-01 Celia MORGAN Ketamine in the treatment of behavioural addictions
CA3225353A1 (en) * 2021-06-25 2022-12-29 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
AU2022374097A1 (en) * 2021-10-18 2024-03-14 Clearmind Labs Corp. 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
WO2023154450A2 (en) * 2022-02-11 2023-08-17 Gilgamesh Pharmaceuticals, Inc. (ampa-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders
CN115677444A (zh) * 2022-10-26 2023-02-03 公安部第三研究所 同位素毒品代谢物标记化合物及其制备方法、用途
AU2023419893A1 (en) * 2022-12-28 2025-07-03 Gilgamesh Pharmaceuticals, Inc. Synthesis of 2-phenyl-2-amino-cyclohexan-1-one derivatives
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
KR20260018914A (ko) * 2023-06-05 2026-02-09 길가메쉬 파마슈티컬스, 인코포레이티드 2-페닐-2-아미노시클로헥산-1-온 유도체의 결정성 염
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de) * 1967-09-19 1971-07-22 Parke Davis & Co 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
AU2003249584B9 (en) 2002-06-21 2008-05-15 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
AU2003249583B2 (en) 2002-06-21 2007-06-07 Suven Life Sciences Limited Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
BR0312176A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1912970A2 (en) 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CN102046591B (zh) 2008-03-27 2014-12-03 格吕伦塔尔有限公司 羟甲基环己胺
EP2385944A4 (en) 2009-01-09 2013-06-19 Harvard College FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF
WO2010136546A1 (en) 2009-05-27 2010-12-02 Université Libre de Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
KR102104953B1 (ko) * 2018-04-17 2020-04-27 삼육대학교 산학협력단 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
CN115190815B (zh) * 2019-12-26 2024-06-18 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
CN112174851A (zh) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Similar Documents

Publication Publication Date Title
JP2023527575A5 (https=)
JP2023508469A5 (https=)
JPWO2023084749A1 (https=)
CN305530808S (https=)
CN305531109S (https=)
CN305534307S (https=)
CN305530862S (https=)
CN305529602S (https=)
CN304999651S8 (https=)
CN306788160S (https=)
CN306353611S (https=)
CN306166360S (https=)
CN305864072S (https=)
CN305740790S (https=)
CN305736695S (https=)
CN305735562S (https=)
CN305734372S (https=)
CN305733924S (https=)
CN305732880S (https=)
CN305724248S (https=)
CN305723460S (https=)
CN305722384S (https=)
CN305706608S (https=)
CN305705987S (https=)
CN305705356S (https=)